Artiva Biotherapeutics (ARTV) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 126.7% versus a loss of 13.9%. Kyverna Therapeutics is the larger company by market cap ($389.6 million vs $338.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | KYTX |
|---|---|---|
| Share price | $6.93 | $6.30 |
| Market cap | $338.56M | $389.61M |
| 1-day change | +1.84% | +1.94% |
| YTD return | +58.51% | -34.26% |
| 1-year return | +126.67% | -13.93% |
| EPS (TTM) | $-3.23 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $13.67 |
| 52-week low | $2.71 | $5.96 |
| Distance from 52-week high | -52.34% | -53.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +416.97% | +382.54% |
| Average volume | 403.56K | 903.83K |
| Shares outstanding | 48.89M | 61.84M |
| Employees | 115 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed KYTX by 140.6 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
ARTV vs KYTX FAQ
Which is bigger, Artiva Biotherapeutics or Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $389.61M compared with $338.56M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ARTV or KYTX?
ARTV returned +126.67% over the past 12 months, compared with -13.93% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.